<DOC>
	<DOCNO>NCT02492165</DOCNO>
	<brief_summary>The purpose study describe immunogenicity safety IMOJEV® adult pediatric population Vietnam serve bridge study compare immunogenicity , reactogenicity , safety data obtain IMOJEV® Vietnamese population data Asian pediatric population . Primary objective : - To describe safety profile single dose IMOJEV® . Secondary objective : - To evaluate immune response JE 28 day administration single dose IMOJEV® healthy Vietnamese subject age 9 month 60 year .</brief_summary>
	<brief_title>Study Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine ( IMOJEV® ) Healthy Subjects</brief_title>
	<detailed_description>Study participant enrol age group receive one injection IMOJEV® Day 0 give primary vaccination . They assess immunogenicity safety , post-vaccination .</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Japanese</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 9 month 60 year day inclusion . For adult : Informed consent form sign dated subject . For minor : Informed consent form sign dated parent legally acceptable representative . In addition , accordance Institution Ethics Committee / Institution Review Board requirement appropriate age subject , subject may require sign date inform consent form age 12 17 year assent form age 8 11 year . Subject parent ( ) /legally acceptable representative ( ) able attend schedule visit comply study procedure . Subject pregnant , lactating , childbearing potential ( consider nonchildbearing potential , female must premenarche , postmenopausal least 1 year , surgically sterile , use effective method contraception abstinence least 4 week prior vaccination least 4 week vaccination ) . Participation time study enrollment ( 4 week precede study vaccination ) plan participation present study period another clinical study investigate vaccine , drug , medical device , medical procedure . Receipt vaccine 4 week precede study vaccination plan receipt vaccine 4 week follow study vaccination , except inactivate influenza vaccination , may receive least 2 week study vaccine Previous vaccination flavivirus disease , include Japanese Encephalitis ( JE ) , dengue , yellow fever . Receipt immune globulin , blood , bloodderived product past 3 month might interfere assessment immune response . Known suspected congenital acquire immunodeficiency , receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy ( 2 consecutive week within 4 week precede vaccination ) . History flavivirus infection ( confirm either clinically , serologically , virologically ) . History central nervous system disorder disease , include seizure . Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine use study vaccine contain substance . Known thrombocytopenia , contraindicate vaccination . Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate vaccination . Deprived freedom administrative court order , emergency setting , hospitalize involuntarily . Current alcohol abuse drug addiction . Chronic illness , opinion investigator , stage might interfere study conduct completion . Febrile illness ( temperature ≥ 38.0°C ) moderate severe acute illness/infection day vaccination , accord Investigator judgment . A prospective subject include study condition resolve febrile event subside . Receipt chronic antiviral 2 month precede study vaccination plan receipt antiviral 4 week follow study vaccination . Shortterm antiviral drug flu herpes administer provide washout period 1 week administration vaccine . Identified Investigator employee Investigator study center direct involvement propose study , identify immediate family member ( i.e. , parent , spouse , natural adopt child ) Investigator employee direct involvement propose study .</criteria>
	<gender>All</gender>
	<minimum_age>9 Months</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Japanese Encephalitis</keyword>
	<keyword>Japanese encephalitis chimeric virus vaccine</keyword>
	<keyword>IMOJEV®</keyword>
	<keyword>Live attenuate vaccine</keyword>
</DOC>